IP Library Granted Patent US 10,314,865
Granted Patent B2
US 10,314,865 · App. 15/639,767 · Granted Jun 11, 2019

Method and system for treating cancer and other age-related diseases by extending the healthspan of a human

Inventors: Katherine Rose Kovarik (Englewood, CO); Joseph E. Kovarik (Englewood, CO)
A61K35/74A61K9/0014A61K9/0034A61K9/0043A61K9/0053A61K31/366A61K31/40A61K31/436A61K31/438A61K31/505A61K31/58A61K35/741A61K35/742A61K35/745A61K35/747A61K38/1758A61K38/465A61K39/07A61K39/35A61K45/06C12Y301/03048C12Y301/03067A61K2035/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,314,865
App. No.
15/639,767
Granted
Jun 11, 2019
Kind
B2
Abstract

Various embodiments of the present invention are directed to the field of Oncology, and in particular, embodiments directed to a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancerous cells. Certain embodiments are directed to the field of human longevity and aging in a manner such that cancer is not contracted due to ameliorating, treating, or reducing aging by increasing the healthspan and lifespan of humans. In certain embodiments, administration of beneficial bacteria to an individual's microbiome that have been modified so as to produce effective amounts of desired compositions, compounds, agents, e.g. tomatidine, rapamycin, p53 protein, statins, etc., is employed to treat and prevent cancer and other age-related diseases.

Claims (14)

1. A method of treating bladder cancer in a subject in need of such treatment, said method comprising administering to a gut microbiome of a subject with bladder cancer an effective amount of a bacterial composition comprising bacillus calmette - guerin , said bacterial composition comprising bacteria adapted to produce p53.

2. The method of claim 1 , wherein the bacterial composition comprises bacteria modified via a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system using a CRISPR-Cas system to express p53.

3. The method of claim 1 , wherein the bladder cancer is a metastatic cancer.

4. A method of claim 1 , wherein said bacterial composition further includes a microbe selected from the group consisting of Streptococcus, Veillonella, Fusobacterium and Treponema.

5. The method as set forth in claim 4 , further comprising administering to the subject at least 0.1 mg of rapamycin.

6. The method of claim 1 , wherein a bacterium in the bacterial composition has been modified via a CRISPR-Cas system to express p53.

7. The method of claim 1 , wherein the bacterial composition further comprises a bacterium selected from the group consisting of Chlamydia, Shigella flexneri, Mycoplasma bacteria , and H. pylori.

8. The method of claim 1 , wherein the bacterial composition comprises H. pylori bacteria.

9. A method of treating bladder cancer in a subject in need of such treatment, said method comprising administering to a gut microbiome of a subject with bladder cancer an effective amount of a bacterial composition comprising a bacteria that has been modified to express a therapeutically effective amount of p53, said bacterial composition including bacteria selected from the group consisting of Streptococcus, Veillonella, Fusobacterium and Treponema.

10. A method of treating bladder cancer in a subject in need of such treatment, said method comprising administering to a gut microbiome of a subject with bladder cancer a bacterial composition comprising a therapeutically effective amount of bacillus calmette - guerin bacteria, wherein the bacillus calmette - guerin bacteria has been modified using a CRISPR-Cas system to produce p53.

11. The method of claim 10 , wherein the bacterial composition comprises Veillonella bacteria.

12. The method of claim 10 , wherein the bacterial composition comprises Streptococcus.

13. The method of claim 10 , wherein said bacterial composition comprises butyrate producing bacteria.

14. The method of claim 10 , wherein the bacterial composition comprises Fusobacterium and Treponema.

Assignments (3)
SECURITY INTEREST Recorded Jul 21, 2026
From: SEED HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A., AS LENDER
Reel/Frame 076028/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2022
From: KOVARIK, JOE
To: SEED HEALTH, INC.
Reel/Frame 059690/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2021
From: KOVARIK, JOSEPH E
To: KOVARIK, JOSEPH E.
Reel/Frame 057819/0661 →
Continuity (30)
Continuation In Part 15437976 · Feb 21, 2017
Continuation In Part 15403823 · Jan 11, 2017
Continuation In Part 15395419 · Dec 30, 2016
Continuation In Part 15392173 · Dec 28, 2016
Continuation In Part 15385278 · Dec 20, 2016
Continuation In Part 15384716 · Dec 20, 2016
Continuation In Part 15378425 · Dec 14, 2016
Continuation In Part 15342642 · Nov 3, 2016
Continuation In Part 15228454 · Aug 4, 2016
Continuation In Part 15639767
Continuation In Part 15200210 · Jul 1, 2016
Continuation In Part 14954074 · Nov 30, 2015
Continuation 14752192 · Jun 26, 2015
Continuation In Part 14574517 · Dec 18, 2014
Continuation In Part 14283459 · May 21, 2014
Continuation In Part 14225503 · Mar 26, 2014
Continuation 13367052 · Feb 6, 2012
Provisional Application 62296186 · Feb 17, 2016
Provisional Application 62275341 · Jan 6, 2016
Provisional Application 62274550 · Jan 4, 2016
Provisional Application 62387405 · Dec 24, 2015
Provisional Application 62387404 · Dec 24, 2015
Provisional Application 62260906 · Nov 30, 2015
Provisional Application 62072476 · Oct 30, 2014
Provisional Application 62053926 · Sep 23, 2014
Provisional Application 62014855 · Jun 20, 2014
Provisional Application 61919297 · Dec 20, 2013
Provisional Application 61556023 · Nov 4, 2011
Provisional Application 61439652 · Feb 4, 2011
Related Publication 20170348359A1 · Dec 7, 2017
Cited By (9)
US 12,246,043 US 12,257,272 US 12,279,989 US 12,318,411 US 12,318,414 US 12,329,783 US 12,357,662 US 12,533,312 US 12,558,384